Author

S. Libard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

A. Dimberg· 2 shared A. S. Jakola· 2 shared A. Smits· 2 shared A. Vaccaro· 2 shared M. Essand· 2 shared M. Ramachandran· 2 shared T. Olsson Bontell· 2 shared T. van de Walle· 2 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Dimberg

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cellular and molecular events organizing the assembly of tertiary lymphoid structures in glioblastoma

A. Vaccaro, F. Yang, T. van de Walle, S. Franke, R. Lugano, A. Denes, A. Magoulopoulou, I. Cid-Farina, A. Smits, L. Uhrbom, S. Libard, F. Latini, M. Essand, M. Nilsson, L. He, , A. Dimberg

This study identifies cellular and molecular mechanisms of tertiary lymphoid structure (TLS) formation in glioblastoma, showing TLS correlate with improved survival and are driven by CD4 T cells expressing lymphotoxin β.

bioRxiv · Jul 4, 2024 · PreprintCancer Biology

Agonistic CD40 antibody therapy induces tertiary lymphoid structures but impairs the response to immune checkpoint blockade in glioma

L. van Hooren, A. Vaccaro, M. Ramachandran, K. Vazaios, S. Libard, T. van de Walle, M. Georganaki, H. Huang, I. Pietilä, J. Lau, M. H. Ulvmar, M. C. Karlsson, M. Zetterling, S. M. Mangsbo, A. S. Jakola, , A. Dimberg

This study shows that agonistic CD40 antibody therapy in glioma models causes T cell dysfunction and reduces response to checkpoint inhibitors, but also promotes tertiary lymphoid structures associated with improved T cell infiltration.

bioRxiv · Jan 5, 2021Cancer Biology